FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/09/2022
Voltar para busca
Dado oficial do USPTO
KD-PÜR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
05/09/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42
Data de depósito
22/07/2020
Data de registro
22/03/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/03/2022
Última transação
22/03/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
27
Localização do titular
DE
Examinador
CLARKE, NANCY
Unidade examinadora
L20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
K.D. Pharma Bexbach GmbH
Representantes
Christian Wolff Schock Rechtsanwaelte GbR
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary productspharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorderspharmaceutical products for the prevention and treatment of cancerpharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorderspharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti - infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccineschemical reagents for medical or veterinary purposes; sanitary preparations for medical use; dietetic foodstuffs and preparations for medical or veterinary purposesdietetic foods and beverages adapted for medical usedietetic foods adapted for veterinary usedietetic beverages adapted for veterinary usedietetic preparations adapted for medical purposes; dietary supplements for humans and animals; pharmaceutical products in the nature of oilspowders and capsules containing omega-3-extracts for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; nutritional supplements; dietetic preparations adapted for medical purposes containing omega-3-extracts and in the form of oilspowders and capsules containing omega-3-extracts
Classe 40
Contract manufacturing for others of pharmaceutical productsdietary supplements and dietetic products for medical purposes containing omega-3-extracts in the form of oilspowders and capsules
Classe 42
Scientific and technological servicespharmaceutical research and developmentpharmaceutical products developmenttesting of pharmaceuticalsdevelopment of pharmaceutical preparations and medicinesscientific research in the field of pharmaceuticalspharmaceutical research serviceslaboratory research services relating to pharmaceuticalsscientific analysis in the field of nutritional supplements; scientific research and development in the field of lipid extraction from natural resources; scientific laboratory services; chemical laboratories; scientific and industrial research for others relating to the manufacture of pharmaceutical productsdietary supplements and dietetic products for medical purposes containing omega-3-extracts in the form of oilspowders and capsules
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
16/08/2022
FIMP
FINAL DISPOSITION PROCESSED
16/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
22/06/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
22/03/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
21/03/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/03/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/03/2022
GPNX
NOTIFICATION PROCESSED BY IB
22/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/01/2022
PUBO
PUBLISHED FOR OPPOSITION
04/01/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/12/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
15/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/11/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/11/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
25/11/2021
DMCC
DATA MODIFICATION COMPLETED
01/06/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/06/2021
GNFR
FINAL REFUSAL E-MAILED
01/06/2021
CNFR
FINAL REFUSAL WRITTEN
01/06/2021
ALIE
ASSIGNED TO LIE
01/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/05/2021
RFNT
REFUSAL PROCESSED BY IB
13/12/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/11/2020
RFRR
REFUSAL PROCESSED BY MPU
24/11/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/11/2020
CNRT
NON-FINAL ACTION WRITTEN
07/11/2020
DOCK
ASSIGNED TO EXAMINER
06/11/2020
MAFR
APPLICATION FILING RECEIPT MAILED
03/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/09/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/09/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KD-PÜR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.